Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

The effect of long-term alendronate treatment on cortical thickness of the proximal femur.

Unnanuntana A, Ashfaq K, Ton QV, Kleimeyer JP, Lane JM.

Clin Orthop Relat Res. 2012 Jan;470(1):291-8. doi: 10.1007/s11999-011-1985-9. Epub 2011 Jul 20.

2.

Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures.

Napoli N, Jin J, Peters K, Wustrack R, Burch S, Chau A, Cauley J, Ensrud K, Kelly M, Black DM.

J Clin Endocrinol Metab. 2012 Jul;97(7):2414-22. doi: 10.1210/jc.2011-3256. Epub 2012 Apr 30.

3.

Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy.

Ng YH, Gino PD, Lingaraj K, Das De S.

Injury. 2011 Jul;42(7):702-6. doi: 10.1016/j.injury.2010.12.019. Epub 2011 Feb 11.

PMID:
21316051
4.

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM.

Osteoporos Int. 2009 Aug;20(8):1353-62. doi: 10.1007/s00198-008-0805-x. Epub 2008 Dec 9.

5.

The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women.

Mobini M, Dehghan L, Yosefi G, Mohammadpour A, Abdi R.

Med J Islam Repub Iran. 2016 Feb 15;30:328. eCollection 2016.

6.

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Kwek EB, Goh SK, Koh JS, Png MA, Howe TS.

Injury. 2008 Feb;39(2):224-31. doi: 10.1016/j.injury.2007.08.036. Epub 2008 Jan 28.

PMID:
18222447
7.

Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases.

Ballas EG, Mavrogenis AF, Karamanis E, Kokkalis ZT, Mitsiokapa E, Koulalis D, Mastrokalos D, Papagelopoulos PJ.

Eur J Orthop Surg Traumatol. 2015 Jan;25(1):181-7. doi: 10.1007/s00590-014-1443-y. Epub 2014 Mar 28.

PMID:
24676887
8.

Case reports: two femoral insufficiency fractures after long-term alendronate therapy.

Sayed-Noor AS, Sjödén GO.

Clin Orthop Relat Res. 2009 Jul;467(7):1921-6. doi: 10.1007/s11999-009-0725-x. Epub 2009 Feb 6.

9.

Cortical thickness of the femur and long-term bisphosphonate use.

Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A.

J Bone Miner Res. 2015 Feb;30(2):225-31. doi: 10.1002/jbmr.2345.

10.

Letter to the editor: the effect of long-term alendronate treatment on cortical thickness of the proximal femur.

Koh JS, Ng AC, Png MA, Howe TS.

Clin Orthop Relat Res. 2011 Dec;469(12):3509-10; author reply 3511-12. doi: 10.1007/s11999-011-2129-y. No abstract available.

11.

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.

Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R.

Drug Saf. 2009;32(9):775-85. doi: 10.2165/00002018-200932090-00002.

PMID:
19670917
12.

A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.

Cross MB, Nam D, van der Meulen MC, Bostrom MP.

J Bone Joint Surg Br. 2012 Jul;94(7):994-7. doi: 10.1302/0301-620X.94B7.28778.

PMID:
22733959
13.

Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy.

Çakmak S, Mahiroğulları M, Keklikçi K, Sarı E, Erdik B, Rodop O.

Acta Orthop Traumatol Turc. 2013;47(3):162-72.

14.

A rational approach to management of alendronate-related subtrochanteric fractures.

Das De S, Setiobudi T, Shen L, Das De S.

J Bone Joint Surg Br. 2010 May;92(5):679-86. doi: 10.1302/0301-620X.92B5.22941.

PMID:
20436006
15.

Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.

Capeci CM, Tejwani NC.

J Bone Joint Surg Am. 2009 Nov;91(11):2556-61. doi: 10.2106/JBJS.H.01774.

PMID:
19884427
16.

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS.

J Bone Joint Surg Br. 2007 Mar;89(3):349-53.

17.

Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures.

Chen F, Wang Z, Bhattacharyya T.

Bone. 2014 May;62:64-6. doi: 10.1016/j.bone.2014.01.011. Epub 2014 Jan 25.

18.

Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.

Bamrungsong T, Pongchaiyakul C.

J Med Assoc Thai. 2010 May;93(5):620-4.

PMID:
20524451
19.

Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.

Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M.

J Orthop Res. 2009 Feb;27(2):183-8. doi: 10.1002/jor.20748.

20.

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.

Pazianas M, Abrahamsen B, Wang Y, Russell RG.

Osteoporos Int. 2012 Dec;23(12):2873-84. doi: 10.1007/s00198-012-1952-7. Epub 2012 Mar 20.

PMID:
22431012

Supplemental Content

Support Center